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Lack of Clinically Significant Improvement of 
Patients with Tardive Dyskinesia Following 
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Benjamin Mathews, Sandi Tait, and Beverly Kovacic 
A double-blind controlled study was undertaken to examine the value ofphosphatidyl- 
choline as a treatment for tardive dyskinesia (TD) in 19 psychiatric patients. All patients 
were maintained on their usual psychotropic medication throughout the entire study. In 
addition, they were given either phosphatidylcholine (30 g/day) or placebo for 6 weeks. 
Thirteen of the patients received the crossover treatment for 6 weeks, after which 10 of 
the 13 were continued on the crossover medication for an additional 6 weeks. At the end 
of the study, 5 patients had received phosphatidylcholine for 12 weeks and another 12 
patients had received the drug for only 6 weeks. Plasma and red blood cell choline levels 
were monitored every 3 weeks as a measure of compliance. Although some patients 
showed clinical improvement of their TD, the results did not differ significantly between 
active drug and placebo. This was in spite of a marked elevation of plasma and red blood 
cell choline (up to 300% for the Lafayette Clinic patients and up to 400% for the patients 
from the Ypsilanti Regional Psychiatric Hospital) during treatment with phosphatidyl- 
choline. Side effects of the drug included occasional gastrointestinal upsets and diarrhea 
but, in general, the medication was tolerated very well. The results indicate that large 
doses of phosphatidylcholine of soya origin are of no clinical value in treating symptoms 
of TD in spite of very large increases in blood choline. 
Introduction 
The report by Hirsch and Wurtman (1978) that dietary lecithin (phosphatidylcholine) can 
elevate brain levels of acetylcholine (ACh) prompted a number of investigators (see 
reviews by Jeste and Wyatt 1982a,b; Alphs and Davis 1983), including the authors, to 
assess lecithin as a treatment for tardive dyskinesia (TD). The rationale behind such 
treatment is based on evidence that TD is characterized by a relative functional deficit 
of striatal cholinergic activity (Klawans 1973). Choline released from the lecithin molecule 
might serve as a precursor for brain ACh and restore central cholinergic activity. 
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Open studies on the use of lecithin as a treatment for TD tend to report favorable 
results (Alphs and Davis 1983). Blind studies (Table 1) have produced variable results. 
The present report is of a blind, placebo-controlled study on the treatment of TD with 
a relatively pure form of lecithin (94% phosphatidylcholine) for a reasonable period of 
time (6 or 12 weeks). 
M e t h o d s  
Nineteen male or female patients with a diagnosis of TD were recruited from the south- 
eastern area of Michigan for study as either inpatients or outpatients at the Lafayette 
Clinic (LC) or as inpatients at Ypsilanti Regional Psychiatric Hospital (Ypsi). Approval 
to conduct the study was obtained from the institutional review boards of LC and Ypsi. 
A diagnosis of TD was established by at least one neurologist and one psychiatrist. A 
patient was included in the study only if all of the physicians involved with the patient 
agreed that he or she had TD and only if the patient's informed consent was obtained. 
Psychiatric diagnoses were: 15 patients with schizophrenia, 2 with bipolar affective illness, 
1 with senile dementia, and 1 with presenlle dementia. All patients were maintained on 
their usual psychotropic medications throughout the entire study. Ages of the patients at 
the LC ranged from 30 to 66, with an average of 60 years; at Ypsi they ranged from 46 
to 84, with an average of 67 years. Thus, the latter were somewhat older and all were 
inpatients. However, severity of the TD was similar between the two hospital groups of 
patients. 
Phosphatidylcholine was administered in the form of Phospholipon 100 (American 
Lecithin Co., Atlanta, GA), which contains 94% phosphatidylcholine. The drug was 
dissolved in 0.9% NaC1, forming a solution that looks like evaporated milk. Placebo 
solution consisted of evaporated milk plus malt. Drug or placebo solution was dispensed 
to hospital staff or to outpatients who then used it in simple recipes calling for major 
ingredients of either cold milk, ice cream, sherbet, or frozen yogurt. 
Rating scales employed were adapted from the "Early Clinical Drug Evaluation Unit 
Assessment Manual" (Guy 1976) and were as follows: Abnormal Involuntary Movement 
Scale (AIMS), Physician's Global Impression of Patient's Mental Illness, Nurse's Global 
Impression of Patient's Mental Illness, and the Emergent Symptom Scale (ESS). The 
rating scales were scored on the basis of live contact with the patient. Interrater reliability 
varied from 0.7 to 0.9 with a mean of about 0.8. Subsequently, at scheduled times, 
videotapes of the patients were obtained under standardized conditions for later counting 
of abnormal movements by a single trained technician who was unaware of the current 
treatments. The videotapes were presented to him in a randomized order within and across 
patients. 
Plasma and red blood cell choline were measured by gas chromatography-nitrogen 
phosphorus detection after chemical demethylation (Kosh et al. 1979; Jenden et al. 1968). 
Trimethylaminopropanol was used as the internal standard (Buchanan et al. 1980). 
All patients were treated for 6 weeks with either phosphatidylcholine (30 g/day) or 
placebo. Three patients at LC were given the crossover treatment for 6 weeks. All 10 of 
the Ypsi patients were given the crossover treatment for 12 weeks. At the end of the 
study, out of the total of 19 patients, 5 had received phosphatidylcholine for 12 weeks 
(at Ypsi) and another 12 patients had received the drug for only 6 weeks (5 at Ypsi and 
7 at LC). A battery of data was obtained 1-3 times before each treatment and once after 
the 3rd, 6th, and, where applicable, the 12th week of treatment. A 1-3-month washout 
period was allowed between treatments. 
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Figure 1. Effects of oral soya phosphatidylcholine on blood choline levels in patients with tardive 
dyskinesia (Lafayette Clinic study). A total of  nine patients were given lecithin in their diet for 6 
weeks. Plasma (P) and red blood cell (RBC) choline levels were determined under double blind 
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Figure 2. Effects of oral soya phosphatidylcholine on blood choline levels in patients with tardive 
dyskinesia (Ypsilanti Regional Psychiatric Hospital study). Five patients were given lecithin and 
another five were given placebo in their diet for 6 weeks; all were given the crossover treatment 
for 12 weeks. The choline levels were elevated from about 10 to 40 nmol/ml in plasma and from 
40 to 150-180 nmol/ml in their red blood cells. 
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Mean and SE of all of  the measures were calculated and the data compared using 
Student's t-test (Snedecor 1956). Differences among the repeated observations in the 
same patients were analyzed for matched pairs (correlated t-test). Measures compared 
across patient groups were based on independent means (uncorrelated t-test). 
Results 
Phosphatidylcholine dramatically elevated plasma and red blood cell choline compared 
with placebo in both the LC and Ypsi patients, as shown in Figures 1 and 2. The increases 
are statistically significant (p < 0.05) and are greater in the Ypsi than in the LC group 
of patients. In view of the small number of patients from each institution, and in view 
of the similarity of the results, the clinical assessment data of both groups were pooled. 
As can be seen in Figure 3 from the Physician's Global Rating, there was a slight 
psychiatric improvement after 3 weeks of lecithin compared with placebo, which was 
not true after 6 weeks. In contrast, the Nurse's Global Rating scale had no psychiatric 
improvement whatsoever. Interestingly, the Emergent Symptoms Scale indicated that 
after 3 weeks of placebo the patients had fewer side effects than when given lecithin. 
However, lecithin treatment for 6 to 12 weeks did not increase the number of side effects 
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Figure 3. Combined mean data on the Physician's Global Rating, AIMS Test, Nurse's Global 
Rating, and Emergent Symptoms Scale. Each score represents the mean + SE of approximately 
19 patients. *p < 0.05 compared with baseline scores. 
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compared with placebo. Insofar as motor movements were concerned, based on the 
Abnormal Involuntary Movement Scale, they seemed to be decreased after both placebo 
and lecithin at 3 weeks (p < 0.05), but not at 6 weeks of lecithin therapy. 
When mouth movements were counted from observation of the videotapes under four 
conditions (quiet, mouth open, tongue out, and finger tapping), no consistent improvement 
was observed with either therapy (Figure 4). After 6 weeks of lecithin, the patient's 
mouthing movements (mouth open, tongue out) actually appeared somewhat worse 
(p < 0.05). 
Discussion 
Results of this study are very clear. Oral phosphatidylcholine therapy raised plasma and 
red blood cell choline levels to at least 300% above baseline at both 3 and 6 weeks. In 
contrast, placebo therapy had no effect on blood choline levels. In spite of a marked 
increase in blood choline, phosphatidylcholine therapy did not improve any of the signs 
and symptoms of TD compared with placebo. Blood choline levels were considerably 
greater in the Ypsi inpatients than in the LC inpatients and outpatients (p < 0.05). This 
finding suggests that compliance in the LC patients was lower. However, neither hospital 
group of patients showed any significant improvements so the clinical data were pooled. 
COMBINED MEAN DATA OF MOUTH MOVEMENTS 
(YPSI AND LC CROSSOVERS) 
QUIET 
0 
MOUTH OPEN , 
. o  
.z I I I  






BASELINE 3wk PLACEBO 6wk PLACEBO 3wk LECITHIN 6vdt LECITHIN 
Figure 4. Combined mean data on movements as measured from closed circuit television recordings. 
Means _ SE or mouth movements per minute were obtained for 19 patients, p < 0.05 compared 
with baseline scores. 
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When the results of the present study are combined with those of other blind studies 
on the treatment of TD with lecithin, the ratio of number of lecithin-treated patients who 
improved to total number of lecithin-treated patients is 10:45, i.e., 22%. 
It is clear that lecithin is not a reliable treatment for TD. Speculation as to why this 
is so involves the following considerations. Neither Jope (1982) nor Domino et al. (1983) 
were able to confirm the findings of Hirsch and Wurtman (1978) that in rodents dietary 
lecithin elevates brain levels of ACh; Wurtman and associates, however, were able to 
confirm that finding (Magil et ai. 1981). The ability of peripherally administered choline 
itself to elevate brain ACh is controversial (Brunello et al. 1982). Even if brain ACh is 
increased after precursor loading, there is no guarantee that central cholinergic neuro- 
transmission will also be increased. Some evidence of increased neurotransmission comes 
from the work of Wurtman and associates and of Hanbrich and associates. These inves- 
tigators reported that peripherally administered choline increased brain ACh (Cohen and 
Wurtman 1975; Haubrich et al. 1975) and that such treatment could also cause chemical 
changes in certain neurons (striatal dopaminergic neurons) that receive input from cho- 
linergic neurons; indirect pharmacological evidence indicated that the changes in the 
dopaminergic neurons were due to increased release of ACh from presynaptic terminals 
(Ulus and Wurtman 1976; Haubrich and Pfleuger 1979). However, Eckernas et al. (1977) 
and Brunello et al. (1982) found no indication of increased turnover of brain ACh when 
plasma choline levels were elevated after infusions of labeled choline. In humans, drugs 
affecting cholinergic transmission produce electroencephalographic changes (Itil and Fink 
1968; Pfefferbaum et al. 1979) but no significant changes have been observed after lecithin 
(Rabin et al. 1983; Volavka et al. 1983). In four normal volunteers, lecithin did not 
affect secretion of hormones known to be under cholinergic control (Rabin et al. 1983). 
In view of the foregoing, it seems reasonable to ascribe the negative results of the 
present study to the likelihood either that lecithin did not enhance central cholinergic 
activity or that central cholinergic activity is not involved in the mechanism of tardive 
dyskinesia. It is of interest that the use of lecithin for the treatment of Alzheimer's disease, 
which is unequivocally associated with central cholinergic deficits, also has produced 
predominantly negative results (Johns et al. 1983). Branconnier et al. (1984) have sug- 
gested that one possible explanation for the negative findings with oral lecithin therapy 
in Alzheimer's disease may be a lack of adequate plasma choline concentrations as based 
upon their dose-response analysis of plasma choline to oral lecithin. Clearly the plasma 
choline levels in the TD patients in this study were markedly elevated and thus this 
suggestion is not applicable. 
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